SOST and neoplasm: Since sclerostin can serve as a therapeutic target for myeloma bone disease, preclinical study reveals that anti-sclerostin monoclonal antibodies inhibit tumor growth and bone disease in combination with the proteasome inhibitor carfilzomib [40].